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EFFECTS OF STREPTOLYSIN O ON EXTRACELLULAR MATRIX GENE
EXPRESSION IN NORMAL HUMAN EPIDERMAL KERATINOCYTES
Stephen W. Mamber, PhD, Volkan Gurel, PhD, Ryan G. Rhodes, PhD and John
McMichael, PhD  Beech Tree Labs, PO Box 127, Delanson, NY 12053
 ML-05 is a non-hemolytic form of streptolysin O, the membrane-damaging extracellu-
lar toxin produced by certain streptococci. ML-05 stimulates keratinocyte migration and
proliferation in wound-healing scratch assays and promotes wound healing in a human
skin organ culture wound model. Pathway-focused DNA microarrays were used to eluci-
date ML-05’s mechanism of action in wound healing processes. Normal human epidermal
keratinocytes (NHEK) were treated with varying concentrations of ML-05 for 24 hours, fol-
lowed by RNA extraction and cRNA production. Gene expression profiling utilized
microarrays containing nucleic acid probes for 113 extracellular matrix (ECM) genes.
Microarrays yielded 6 upregulated and 4 downregulated genes with ≥2-fold changes and
p<0.05 in t-tests. Quantitative real-time polymerase chain reactions (qPCR) were used to
verify gene regulation. Upregulated genes of interest were VCAN (formerly CSPG2,
encoding versican), CD44 (encoding hyaluronan receptor), ICAM1 (encoding intercellu-
lar adhesion molecule-1) and CTGF (encoding connective tissue growth factor). All four
upregulated genes encode proteins involved in promoting keratinocyte migration and
proliferation. Downregulated genes of interest were MMP9 (encoding matrix metallopro-
teinase 9) and SPP1 (encoding osteopontin). ML-05 may enhance wound healing through
the expression of specific genes encoding proteins capable of promoting keratinocyte
migration, proliferation, and other activities related to maintaining ECM structure and
function.
INTRODUCTION
Streptolysin O (SLO), a hemolytic exotoxin, is produced by
Streptococcus species of groups A, C & G. Structurally, the SLO primary
gene product is made up of 571 amino acids with several structural and
functional domains. This 60-70 kDa single chain protein can act as a thiol-
activated, cholesterol-binding agent, forming pores in cell membranes in
its reduced state. Red blood cells, being particularly susceptible to cytoly-
sis, are used to determine the cytolytic properties of SLO. Similar cytolyt-
ic toxins are produced by other species of Gram-positive bacteria
(Johnson et al. 1980; Alouf et al. 1984; Bhakdi et al. 1985; Palmer et al.
1996; Harris et al. 1998; Palmer 2001).
ML-05 is a non-hemolytic form of SLO that is produced by oxidation
of the parent molecule. Previous research established that ML-05 marked-
ly enhanced keratinocyte migration and proliferation in in vitro wound
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healing scratch assays and promoted wound reepithelialization in an ex
vivo human skin organ culture wound model (Tomic-Canic et al. 2007).
Interestingly, ML-05 did not affect either migration or proliferation of
human dermal fibroblasts, suggesting that ML-05’s effects on cell migra-
tion/proliferation may have been keratinocyte-specific. ML-05 has also
been shown to modulate the excessive production of collagen in two
murine models of scleroderma, the genetically based tight skin (Tsk)
model and the bleomycin-induced scleroderma model (Mamber et al.
2004).
Based on a survey of the scientific literature, it has been hypothesized
that ML-05 may facilitate the restoration of normal extracellular matrices
within tissues by indirectly or directly altering collagen production. The
beneficial effects of ML-05 on wound healing and/or antifibrotic process-
es may be achieved via several possible mechanisms. First, SLO and relat-
ed compounds may increase or maintain the expression of cell surface
receptors that are involved in extracellular matrix (ECM) organization,
such as hyaluronan receptor CD44 (Mamber et al. 2004; Aruffo et al. 1990;
Lesley et al. 1993; Cichy and Puré, 2003). The pharmacological effects of
low levels of ML-05 on the upregulation of CD44 were characterized in a
previous in vitro study (Mamber et al. 2004). Appropriate changes in the
expression of ECM receptors such as CD44 and subsequent downstream
events within the ECM may promote wound healing (Johnson et al. 2000;
Rilla et al. 2002; Boraldi et al. 2003; Karvinen et al. 2003; Tammi et al.
2005). Second, ML-05 may have beneficial immunomodulatory proper-
ties related to both collagen production and wound healing. SLO and
related substances can induce the production of a variety of cytokines and
chemokines (Houldsworth et al. 1994; Kraakman et al. 1995; Baba et al.
2002; Cockeran et al. 2002; Mitsui et al. 2002; Walev et al. 2002; Stassen et
al. 2003; Kadioglu et al. 2004). As an example of the favorable effects of
cytokines on wound healing processes, interferon-gamma (IFN-γ) and
interleukin-12 (IL-12) have been shown to decrease abnormal collagen
production associated with fibrogenesis (Azouz et al. 2004; Granstein et al.
1987; Granstein et al. 1990; Shi et al. 1997; Ishida et al. 2004). Third, pneu-
molysin, a bacterial protein chemically related to SLO, induced collage-
nase production in fibroblasts at sublytic concentrations (Johnson et al.
1988). Increased collagenase levels may have local effects on abnormal
collagen production and deposition (Arakawa et al. 1996.).
Given the possibility that ML-05 might exert its wound healing and
collagen-modulating effects through ECM-related physiological,
immunological and/or enzymatic mechanisms, it was thought that
genomics-based technologies could be employed to identify differentially
expressed genes involved in mechanisms of action of ML-05. Accordingly,
the objective of this research was to evaluate the effects of ML-05 on ECM
gene expression in normal human epidermal keratinocytes (NHEK cells)
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using pathway-focused DNA microarrays and related gene expression
profiling technologies.
MATERIALS AND METHODS
Streptolysin O and ML-05
Native SLO, purified from Streptococcus pyogenes, was purchased com-
mercially from Sigma Chemicals (St. Louis, MO). A stock solution con-
taining 2,000 U/ml (unit value based on the hemolytic activity of the
starting material) was prepared in sterile deionized water. Oxidation was
achieved by bubbling oxygen into the stock solution, and the final for-
mulation (ML-05) was filtered through a 0.22 μm filter and stored at 4oC
or –20oC. Subsequent dilutions of the stock solution for all experiments
were made in sterile deionized water. Evidence of oxidation was demon-
strated by the lack of activity in hemolysis assays. Standard hemolysis assay
methods were provided by Sigma Chemicals (product literature), except
that sheep red blood cells were employed instead of human red blood
cells. Briefly, microdilution tray wells contained reaction mixtures of 10
mM sodium phosphate, 103 mM sodium chloride, 0.4% (v/v) red blood
cells, 0.4 mg/ml bovine serum albumin, 40 mM dithioerythritol and vary-
ing dilutions of ML-05 (or fresh SLO as the comparator/positive con-
trol). Hemolysis, or lack thereof, was determined visually after incubation
at 37oC for 30 minutes.
Cell Culture and Treatment of Cells with ML-05
Normal human epidermal keratinocytes (NHEK cells) were pur-
chased from Invitrogen (Carlsbad, CA). NHEK cells were expanded to
passage 4 in individual T-25 cell culture flasks using serum-free ker-
atinocyte medium (Invitrogen) supplemented with Epidermal Growth
Factor (5 ng/ml) and Bovine Pituitary Extract (0.05 mg/ml), and main-
tained at 37°C in a 5% CO2 incubator. For the ML-05 treatment experi-
ment, NHEK cells were grown as monolayers in T-25 flasks to about 80%
confluence. At 24 hours prior to ML-05 treatment, the existing cell cul-
ture medium was removed from each flask and replaced with 10 ml of
fresh cell culture media. Cells then were exposed to ML-05 at final con-
centrations ranging from 2 × 10-6 to 2 × 102 units/ml (10-fold dilutions)
for 24 hours. Sterile deionized water was used as a vehicle control and all
exposures were done in triplicate.
RNA Extraction and cRNA Production for Gene Expression Profiling
RNA extraction procedures involved the use of ArrayGradeTM total
isolation RNA analysis kits (SABiosciences [formerly SuperArray
Biosciences], Frederick, MD). For each T-25 flask containing treated
3
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NHEK cells, the medium was removed and cells were lysed directly in the
T-25 flasks with 400 μl of alkaline lysis buffer. The flasks were rocked gen-
tly to permit the alkaline lysis buffer to coat the monolayer and lyse the
cells. For each sample, an aliquot of 350 μl of lysed cells in alkaline lysis
buffer was added to a spin column and total RNA was isolated using the
appropriate reagents and supplies in accordance with procedures recom-
mended by the manufacturer (SABiosciences). The concentration of RNA
in each sample was determined using a QubitTM fluorimeter (Invitrogen),
and representative RNA samples were checked for purity using a
NanodropTM spectrophotometer (Thermo Scientific, Wilmington, DE).
An aliquot of each total RNA sample was added to a separate micro-
centrifuge tube to achieve an RNA amount of 250 ng/tube. Tubes con-
taining RNA were centrifuged briefly, frozen at -80°C, and then evaporat-
ed to dryness using a SpeedVacTM concentrator (Thermo Scientific).
RNA was amplified and converted to cRNA using the TargetAmpTM 1-
Round Biotin-aRNA (cRNA) Amplification Kit (TA-104; Epicentre
Biotechnologies, Madison, WI) in accordance with the manufacturer’s
instructions. SuperScriptTM III reverse transcriptase used with the
TargetAmp kit was purchased from Invitrogen. Briefly, each total RNA
sample (250 ng) was used for first strand cDNA synthesis in the presence
of 50 units of reverse transcriptase. This in turn was used for second
strand cDNA synthesis and each resulting reaction mixture was stored
overnight at -20oC. Next, a combination of biotin labeling and amplifica-
tion during in vitro transcription of the cDNA achieved the production of
sufficient quantities of biotinylated cRNA for microarray hybridizations.
The resulting biotinylated cRNA samples were purified using an
ArrayGrade™ cRNA Cleanup Kit (SABiosciences). The concentration of
each purified cRNA sample was determined with the Qubit TM fluorime-
ter.
DNA Microarrays
Pathway-focused DNA microarrays, specifically Oligo GEArrays®
(SABiosciences), were employed as a means of investigating the effects of
ML-05 on extracellular matrix gene expression (ECM DNA microarrays).
Each ECM DNA microarray consisted of a small nylon membrane con-
taining DNA encoding 113 target DNA sequences for genes known to be
associated with the biological structure and function of the extracellular
matrix. Each membrane was contained within an individual disposable
polypropylene hybridization tube (HybTube). Briefly, for each NHEK
cRNA sample, RNA:DNA hybridizations using the ECM microarrays were
conducted in accordance with the manufacturer’s instructions (2-2.5 μg
of biotin-labeled cRNA were added per individual HybTube). HybTubes
were incubated at 60°C overnight in a standard rotisserie-type hybridiza-
tion oven with three-dimensional rotation. This was followed by several
4
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washing steps as well as incubation of each membrane with alkaline phos-
phatase-streptavidin at room temperature for 10 minutes. The last step of
the procedure involved the addition of a chemiluminescence detection
reagent (CDP-Star®) to each membrane-containing tube (room tempera-
ture incubation for 5 minutes). Results were obtained by photographing
an image of each microarray membrane using a chemiluminescence
CCD camera system (either a Kodak Image Station [Carestream Health,
Rochester, NY] or a ChemiDoc-It® Imaging System [UVP, Upland, CA]).
All resulting microarray images were processed using online gene expres-
sion and analysis software provided by SABiosciences (GEASuite).
Quantitative Real-time Polymerase Chain Reaction (qPCR)
Verification of selected genes of interest that were differentially regu-
lated by DNA microarrays was accomplished by quantitative real-time
polymerase chain reaction (qPCR) techniques employing RT2 qPCR
Primer Assays (SABiosciences). Total RNA from the biological replicate
samples of interest served as the starting material for these assays. RNA
concentrations (OD260) and purities (OD260/OD280) were determined
using a Nanodrop 1000. RNA integrity was established by agarose gel elec-
trophoresis. Reverse transcription PCR (RT-PCR) protocols utilized
reagents obtained from SABiosciences. For each sample, cDNA was gen-
erated using the RT2 First Strand Kit (SABiosciences) according to the
manufacturer’s instructions. Briefly, 500 ng of total RNA was incubated
with the Genomic DNA Elimination Mixture in a 10 μl reaction and incu-
bated for 5 min at 42°C. To generate cDNA, 10 μl of RT Cocktail (con-
taining reverse transcriptase, random hexamers and oligo-dT) was added
and samples were incubated at 42°C for an additional 15 min. Reactions
were stopped by heating at 95°C for 5 minutes. qPCR reactions (25 μl vol-
umes) were carried out using 1 μl of cDNA with the RT2 qPCR Primers
and RT2 SYBR Green/ROX qPCR Master Mix (SABiosciences) according
to the manufacturer’s instructions. Primer catalog numbers
(SABiosciences) were as follows: CD44, PPH00114A; CTGF, PPH00550E;
GAPDH (internal control gene), PPH00150E; ICAM1, PPH00640F;
ITGA4, PPH00659E; MMP9, PPH00152E; SPP1, PPH00582E; and VCAN,
PPH06098B. Reactions were run under the following conditions in an
Mx3005 Quantitative PCR System (Stratagene, La Jolla, CA): One cycle of
95oC for 10 minutes, followed by 40 cycles of 95oC for 15 seconds and
60oC for 1 minute. Fluorescence intensity was measured at the end of
each 60oC cycle, and all experiments included both no-RT and no-tem-
plate controls. Samples were run in triplicate.
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Data Analysis and Statistical Evaluations
The software used with the pathway-focused DNA microarrays yielded
data reflecting levels of the expression of the various genes of interest.
GEASuite data were exported to Microsoft Excel for further data analysis
and evaluation. Genes were classified as upregulated or downregulated
based on fold changes in gene expression relative to control values.
Statistical methods used were based on those described by Cui and
Churchill (2003). First, fold changes in gene expression were calculated
for each gene by dividing the mean treatment value by its corresponding
control value (treatment:control gene expression ratio). Upregulation
was based on treatment:control gene expression ratios of 1.5 (50%
increase) or higher. Whereas, genes were considered downregulated
based on treatment:control gene expression ratios of 0.67 (50%
decrease) or lower. Subsequently, two-tailed t-tests (assuming unequal
variances to compensate for small sample sizes) were performed on each
set of gene expression data (treatment vs. controls) to determine the sta-
tistical significance of the treatment vs. control gene expression values
(p<0.05). These analyses also relied on volcano plots, a graphical means
of combining both fold changes and t-test results into scatter plots of
transformed p-values vs. a transformation of the fold change. Further
data evaluations and selection of genes of interest for verification by
qPCR was accomplished using both standard reviews of the scientific lit-
erature (PubMed; http://www.ncbi.nlm.nih.gov/pubmed/), and
through the use of pathway analysis software (Pathway Studio®; Ariadne
Genomics, Rockville, MD).
For qPCR assays, fold changes in genes of interest for the treatment
samples relative to untreated controls were calculated by the delta-delta
Ct method as recommended by SABiosciences, along with two-tailed t-
tests to determine the statistical significance (p<0.05) of the fold-change
results. Genes of interest were regarded as upregulated (or downregulat-
ed) in cases where fold change was >1.33 (<0.75) coupled with statistical
significance in an accompanying two-tailed t-test (p<0.05).
RESULTS
Extracellular Matrix Gene Expression in NHEK Cells
Previous research with ML-05 treatment of keratinocytes indicated
that effects on migration and proliferation and on CD44 expression
occurred at concentrations ranging from 0.02-20 U/ml (Tomic-Canic et
al. 2007; Mamber et al. 2004.). However, different effects were optimal at
different concentrations. For example, migration was optimal at 2 U/ml,
while proliferation was optimal at the lowest treatment concentration of
0.02 U/ml and decreased with increasing concentration (Tomic-Canic et
6
Dose-Response: An International Journal, Vol. 9 [2014], Iss. 4, Art. 9
https://scholarworks.umass.edu/dose_response/vol9/iss4/9
S. W. Mamber and others
560
al. 2007). Knowing that a) gene expression profiling provides only a snap-
shot of cellular functions (i.e., mRNA levels) at a given time, b) different
ML-05 concentrations could result in different physiological effects, and
c) optimal effects on cellular functions such as proliferation could occur
at concentrations lower than 0.02 U/ml, it was decided that these initial
gene expression profiling experiments should be concentration-based
rather than temporal in nature. Accordingly, NHEK cells were treated
with one of nine ML-05 concentrations ranging from 2 x 10-6 – 2 x 102
U/ml for a single 24-hour time period. Figure 1 is a volcano plot of the
gene expression results (statistical significance on the y-axis, fold change
on the x-axis) for the 113 ECM microarray genes at all 9 treatment con-
centrations.
For an overview of the effects of ML-05 treatment on ECM gene
expression in NHEK cells, initial (first-pass) evaluations of the results con-
sidered fold changes in preference to t-test results. Tables 1 and 2 list
quantitative data (treatment concentrations, fold changes and t-test p val-
ues) for the upregulated and downregulated ECM genes of interest,
respectively, resulting from the treatment of NHEK with ML-05 based on
1.5-fold (50%) or greater changes (increase/decrease) in treatment:con-
trol gene expression ratios (T/C ratios). There were 18 upregulated
genes (Table 1) and 19 downregulated genes (Table 2). The upregulated
and downregulated genes at each treatment concentration are shown in
Tables 3 and 4, respectively. There were no instances of any of the 27
genes being upregulated at one or more treatment concentrations and
downregulated at other concentrations. Figure 2 shows the numbers of
upregulated and downregulated genes obtained at each treatment con-
centration. The data indicate a biphasic relationship between treatment
concentration and gene regulation at the single 24-hour time point.
Once t-tests were taken into account, there were 9 each of the upregulat-
ed and downregulated genes at p<0.05 (Tables 1 and 2). Further selectiv-
ity was applied using a combination of 2-fold changes and p<0.05. This
yielded 6 upregulated and 4 downregulated genes of interest in NHEK
cells exposed to ML-05, which are shown in Tables 5 and 6, respectively.
Figure 3 is a volcano plot of 6 of the regulated genes that were subse-
quently verified using qPCR methodologies. (All tables and figures are pre-
sented after the References section.)
Verification of Microarray Genes of Interest using qPCR
Seven representative genes of interest from NHEK cells that were
identified as being upregulated (CD44, VCAN, CTGF, ICAM1 and
ITGA4) or downregulated (MMP9 and SPP1) in the pathway-focused
DNA microarrays were selected for verification using qPCR. Results of
qPCR assays for these genes are shown in Tables 5 and 6. VCAN (CSPG2),
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ICAM1 and CTGF were verified as upregulated at 3 of 4, 2 of 4 and 1 of
3 treatment concentrations, respectively. However, CD44 and ITGA4 were
not verified as upregulated in qPCR assays (2 and 1 treatment concentra-
tions, respectively). Both genes of interest that were downregulated in the
microarrays, MMP9 and SPP1, were verified as downregulated by qPCR.
DISCUSSION
Genomics experiments employing pathway-focused DNA microarrays
were conducted to determine the effects of in vitro ML-05 exposure on
the expression of ECM genes in NHEK cells. The initial findings, based
on fold changes of ≥ 1.5 alone to be all-inclusive, revealed 18 upregulat-
ed and 19 downregulated genes at one or more ML-05 concentrations,
for a total of 37 out of 113 genes that were differentially expressed in the
ECM microarray (33%). The majority of fold changes were less than 2.0,
indicating that ML-05 treatment had modest or subtle quantitative effects
on gene expression. These subtle effects could also be visualized in the
volcano plot for all genes (Figure 1) as well as in the volcano plot for key
genes of interest (Figure 3). With respect to the effects of ML-05 concen-
tration on gene expression, a dose-response plot of the numbers of
upregulated and downregulated genes as a function of treatment con-
centration was biphasic in nature (Figure 2). The effects of multiple
exposure times were not investigated in these studies, as this experiment
was designed only to test multiple (nine) concentrations of ML-05 at a
single time point (24 hours). Of particular interest was that the two con-
centrations at which the fewest genes were upregulated or downregulat-
ed (0.02 and 0.2 units/ml) did cause in vitro keratinocyte migration and
proliferation and on ex vivo wound healing in a previous study (Tomic-
Canic et al. 2007). Accordingly, it would be useful to conduct a separate
time-course experiment to determine the effects of shorter ML-05 expo-
sures (e.g., 15 minutes to 12 hours) at selected concentrations on ECM
gene regulation.
The application of t-tests for statistical significance (p<0.05) reduced
the numbers of regulated genes to 9 upregulated and 9 downregulated
(accounting for 16% of the microarray genes). Thus, about half of the
upregulated and downregulated genes that met the selected 1.5-fold-
change criteria did not achieve statistical significance (p<0.05). This may
reflect both the variability obtained between replicates using these
microarray methodologies and the modest fold changes obtained with
ML-05 treatment. These data suggest that these types of microarray assays
should be performed using more than three replicates per treatment
concentration and time point. On the other hand, the majority of differ-
entially regulated genes of interest in the microarrays (based on fold
changes of 1.5 or greater) were active at more than one treatment con-
centration (see Tables 1-4 and Figure 3). It is also noted that no genes
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were upregulated at one or more treatment concentrations and down-
regulated at other concentrations. This indicates a degree of consistency
for the regulated genes at different ML-05 treatment concentrations,
despite the nonlinear dose-response relationships encountered at the sin-
gle 24-hour exposure time.
The use of more selective fold-change criteria (≥2.0) yielded 6 upreg-
ulated and 4 downregulated genes of interest, which represented 9% of
the genes in the microarray and thus provided the primary focus for ver-
ification using PCR methodologies. Based on a combination of a) the
pathway-focused DNA microarray results, b) a review of the literature on
ECM genes and c) ECM information obtained via pathway analysis soft-
ware, 7 representative genes of interest from NHEK cells that were iden-
tified as being upregulated (CD44, VCAN, ICAM1, CTGF and ITGA4) or
downregulated (MMP9 and SPP1) in the microarrays were selected for
data verification using qPCR. The qPCR assays established upregulation
of VCAN, ICAM1 and CTGF and downregulation of both MMP9 and
SPP1 in NHEK cells exposed to ML-05. As with the microarrays, fold
changes for active samples were modest, with average fold changes rang-
ing from 1.3-2.5 for upregulated genes and from 0.6-0.3 for downregulat-
ed genes. As such, the qPCR results provide further evidence of the sub-
tle nature of the effects of ML-05 on the regulation of specific genes of
interest. While CD44 upregulation was observed in the microarray
results, its upregulation was not verified by qPCR. The discrepancy
between the microarray and PCR results for CD44 may be related to a
splice variant issue, as CD44 mRNA is known to undergo alternative splic-
ing to yield splice variants (Hirano et al. 1994; Bell et al. 1998). It has been
noted in the literature that false-negative results for CD44 can be
obtained by RT-qPCR, and recommended that CD44 upregulation should
be demonstrated by other methods (Chen and Wang, 2000). CD44 was
previously shown to be upregulated in NHEK cells by ML-05 treatment
using immunohistochemical methods (Mamber et al. 2004). Accordingly,
the combination of immunological and microarray data provide the evi-
dence that CD44 is upregulated by ML-05. ITGA4 also was not verified as
upregulated by qPCR.
VCAN encodes versican (also known as chondroitin sulfate proteo-
glycan 2; VCAN is an updated nomenclature for the CSPG2 gene), and is
an anti-adhesion molecule involved in cell migration and proliferation
(Wight 2002; Wu et al. 2005; Rahmani et al. 2006). Versican interacts with
hyaluronan in maintaining the structural and functional integrity of the
ECM, as does CD44, which encodes the hyaluronan receptor (Mamber et
al. 2004; Aruffo et al. 1990; Lesley et al. 1993; Cichy and Puré, 2003; Wu et
al. 2005; Rodgers et al. 2003; Yoon and Halper, 2005). The role of CD44
upregulation by ML-05 in cell migration and proliferation was recognized
previously (Mamber et al. 2004; Aruffo et al. 1990; Lesley et al. 1993; Cichy
9
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and Puré, 2003; Johnson et al. 2000; Rilla et al. 2002; Boraldi et al. 2003;
Karvinen et al. 2003; Tammi et al. 2005). However, based on the combined
microarray and qPCR results of the present studies (with 3 of 4 tested
samples verified as upregulated), VCAN may be the more prominent of
the hyaluronan-related genes upregulated in ML-05-treated NHEK cells.
The upregulation of Intercellular adhesion molecule-1 (CD54), the
ICAM1 gene product, can also facilitate wound healing by promoting ker-
atinocyte migration (Nagaoka et al. 2000; Yukami et al. 2007). CTGF
encodes connective tissue growth factor, an ECM protein that contributes
to cell migration and proliferation, and to the production of certain pro-
teins such as integrins (Mercurio et al. 2004; Burgess, 2005; Rachfal and
Brigstock, 2005; Heng et al. 2006). Thus, all three of the qPCR-verified
upregulated NHEK genes, VCAN, ICAM1 and CTGF, along with CD44
(whose upregulation was previously established by immunohistochemical
methods), can be related to keratinocyte migration and proliferation.
This provides a mechanistic basis for the ML-05-induced enhancement of
keratinocyte migration and proliferation that was observed in experi-
ments employing in vitro wound scratch assays (Tomic-Canic et al. 2007).
With respect to the downregulation of genes in NHEK cells treated
with ML-05, matrix metalloproteinase gene MMP9 was downregulated
both in the microarrays and in qPCR assays. Metalloproteinase genes
MMP1, MMP2 and MMP10 were also downregulated in the microarrays
at several concentrations, but the combination of fold changes and t-test
results did not meet the criteria established for qPCR verification. For
example, the strongest microarray results for MMP2 (T/C ratio of 0.58,
p<0.05) was slightly above the activity criteria established for these stud-
ies. The protein encoded by MMP9, matrix metalloproteinase 9 (also
known as gelatinase B), acts by degrading certain types of proteins within
the ECM (gelatin and type IV collagen in particular) as well as certain
receptor proteins at the surface of the cell (Opdenakker 1997; Nguyen et
al. 2001; Opdenakker et al. 2001). Although MMPs in general have a role
in tissue remodeling, some have been involved in pathological processes
(Giannelli et al. 1996; Crowe and Brown, 1999; Bellosta et al. 2003; Lakka
et al. 2003; El-Shabrawi et al. 2004; Kim et al. 2005; Jansen et al. 2007). By
protecting key ECM proteins from proteolytic cleavage, downregulation
of MMP9 (and other MMPs, notably, MMP2) may have utility in the treat-
ment of pathological conditions such as fibrosis in which MMPs may be
involved (Giannelli et al. 1996; Crowe and Brown, 1999; Bellosta et al.
2003; Lakka et al. 2003; El-Shabrawi et al. 2004; Kim et al. 2005; Jansen et
al. 2007). Moreover, MMP9 can be downregulated through the interac-
tion of CD44 and hyaluronan (Spessotto et al. 2002). CTGF also is capa-
ble of modulating the production of both matrix metalloproteinases and
tissue inhibitors of metalloproteinases within the ECM (Brigstock 2002;
Black et al. 2003). Accordingly, it is speculated that ML-05 treatment
10
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could result in the preferential downregulation of MMP9, as well as down-
regulating the activity of other detrimental MMPs. SPP1, the other gene
of interest whose downregulation was verified by RT-qPCR, encodes
secreted phosphoprotein type 1, commonly known as osteopontin. This
ECM glycoprotein is upregulated in inflammatory responses as well as in
autoimmune diseases (Collins et al. 2004; Pardo et al. 2005). The down-
regulation of SPP1 is known to decrease inflammation and fibrosis (Mori
et al. 2008).
It was observed that 9 of the 18 upregulated genes encoded different
types of collagens, although selectivity criteria excluded these from qPCR
verification. However, this potential upregulation may explain a finding
from a previous in vivo experiment involving the effects of ML-05 on col-
lagen levels in the tight skin (Tsk) mouse model of scleroderma (Mamber
et al. 2004). Hydroxyproline levels (a measure of collagen concentration)
in skin samples from the ML-05 treatment group of Tsk mice averaged
43% higher relative to that in the saline control group at 4 and 5 months
post-treatment initiation. Then, a 25% decrease in hydroxyproline levels
was obtained in samples from the ML-05 treatment group relative to the
control group at 6–8 months. These differences led to speculation that
ML-05 could promote the synthesis of new collagen along with the loss of
fibrotic collagen structures. The current microarray results for the colla-
gen genes, if confirmed in subsequent studies, may provide some evi-
dence that ML-05 treatment can facilitate fresh collagen synthesis in addi-
tion to its other biological effects.
In summary, treatment of NHEK cells with ML-05 resulted in the
upregulation of several ECM genes (notably VCAN, CD44, ICAM1 and
CTGF) whose encoded proteins are directly involved in promoting ker-
atinocyte migration and proliferation. ML-05 also downregulated MMP9
and SPP1, which encode proteins with potentially detrimental roles in
wound healing. These results provide a mechanistic basis for explaining
how ML-05 could promote keratinocyte migration, proliferation and
other activities related to ECM organization and wound healing. It is
hypothesized that the regulation of these genes by ML-05 could effect
physiological changes in the keratinocytes that may ultimately result in a
restoration of normal ECM organization during the wound healing
process. Further experiments are being conducted to confirm the regu-
latory effects of ML-05 on the genes of interest identified in these studies.
In addition to the regulation of the above-named ECM genes and other
genes of interest, ML-05 treatment of NHEK cells also may affect the
expression of specific cytokine, chemokine and related immune response
genes that are associated with wound repair. Experiments to evaluate the
effects of ML-05 on immune response gene expression, as well as investi-
gations using other types of cells, such as normal human dermal fibrob-
lasts and peripheral blood mononuclear cells, are also being conducted.
11
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ML-05 treatment appears to regulate the expression of specific ECM
genes in complex yet logical ways. It is possible that relationships can be
established between the ECM and immune response proteins encoded by
the respective genes of the different types of cells that are involved in
wound healing processes.
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FIGURE 1. Volcano plot of the effects of ML-05 on ECM microarray gene expression at all 9 treat-
ment concentrations. This plot incorporates both fold-change (log of the treatment/control ratio on
the x-axis) and statistical significance (-log of the t-test p-value on the y-axis). The vertical red and
green lines show where fold change = 2, and the horizontal black line shows where p = 0.05.
Accordingly, upregulated and downregulated genes of interest occupy the upper right and upper left
quadrants, respectively. 
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FIGURE 3. Volcano plots of 6 specific genes of interest highlighting the upregulation and downreg-
ulation of these genes by ML-05 at all 9 treatment concentrations. Upregulated genes are VCAN
(square), ICAM1 (X), CTGF (triangle) and CD44 (diamond). Downregulated genes are MMP9 (star)
and SPP1 (circle). These results highlight the subtle regulatory effects of ML-05 on these 6 genes of
interest, based on both fold change and statistical significance. 
FIGURE 2. Numbers of upregulated (circle) and downregulated (square) ECM genes in microarrays
as a function of ML-05 treatment concentration, based on fold change ≥ 1.5 (upregulated) or ≤ 0.67
(downregulated). 
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TABLE 3. Upregulated ECM genes of interest from NHEK cells (microarray fold change ≥ 1.5) as a
function of ML-05 treatment concentration. (Gene descriptions and quantitative microarray data
are shown in Table 1.) 
Upregulated Treatment Concentrations, U/ml
Genes
Symbol 2.0E-06 2.0E-05 2.0E-04 2.0E-03 2.0E-02 2.0E-01 2.0E+00 2.0E+01 2.0E+02
ADAMTS1 X X X X
CD44 X X X X X X
CNTN1 X
COL12A1 X X X X X
COL18A1 X X X X X
COL1A1 X X
COL4A2 X X X X X X
COL4A6 X
COL5A3 X X X X X X
COL6A1 X
COL8A1 X X X X
COL9A1 X
CTGF X X X X X
ICAM1 X X X X X
ITGA4 X X X X X X
ITGA5 X
VCAM1 X
VCAN X X X X X X X X
(CSPG2)
TABLE 4. Downregulated ECM genes of interest from NHEK cells (microarray fold change ≤ 0.67)
as a function of ML-05 treatment concentration. (Gene descriptions and quantitative microarray
data are shown in Table 2.) 
Downregulated Treatment Concentrations, U/ml
Genes
Symbol 2.0E-06 2.0E-05 2.0E-04 2.0E-03 2.0E-02 2.0E-01 2.0E+00 2.0E+01 2.0E+02
ADAMTS1 X X X X
ITGA2B X X X X
ITGAM X X X
ITGB1 X X X X X
ITGB4 X X X X X
LAMA3 X X X X X X
LAMB3 X
MMP1 X X X X X
MMP10 X X
MMP2 X X
MMP9 X X
PECAM1 X
SELP X X
SGCE X X X
SPARC X X X
SPOCK1 X X
SPP1 X X X X X X X
THBS2 X X X X X X
TIMP1 X X X X X X
TIMP3 X
23
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